P2X7 RECEPTOR ANTAGONISTS MARKET ANALYSIS

P2X7 Receptor Antagonists Market, by Drugs (AKP-23494954/RQ-00466479, EVT 401, GSK1482160, JNJ-55308942, JNJ-54175446, and Others (e.g.- AZ11657312)), by Application (Central Nervous System Disorders, Immunological Disorders, and Others), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) - Size, Share, Outlook, and Opportunity Analysis, 2022-2028

Published In : May 2019
Code : CMI2595
Pages :94
Formats :
Excel and PDF
Industry : Pharmaceutical

Leading Companies

Manufacturers such as GlaxoSmithKline Plc, Johnson and Johnson, AstraZeneca plc, Asahi Kasei Corporation, and others have potential molecules in the pipeline.

Asahi Kasei Corporation, AstraZeneca Plc, and RaQualia Pharma Inc. have their products in preclinical stages for various indications such as analgesics, inflammation, and other indications.

GlaxoSmithKline Plc, Johnson & Johnson, and Evotec AG have these molecule for indications such as pain conditions, inflammatory conditions, major depressive disorder, and mood disorders.

Although, these molecules are in early stages of development, and faster clinical trials and active interest by companies such as Evotec AG, and Asahi Kasei Pharma to advance the pipeline is expected to support growth of the global P2X7 receptor antagonists market over the forecast period.

Some of the major players operating in the global P2X7 receptor antagonist market include, GlaxoSmithKline Plc, Johnson & Johnson, AstraZeneca Plc, RaQualia Pharma, Evotec AG, and Asahi Kasei Corporation.